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Herpes zoster, or shingles, is a painful blistering rash caused by reactivation of varicella zoster virus 
(VZV), the causative agent in chickenpox.    Shingles typically presents in one area on one side of 
the body, in the distribution of a nerve.  There are usually no fever or other systemic symptoms.  
Pain and itching in the area of the shingles may persist after the lesions have resolved (post-herpetic 
neuralgia).  Shingles can be treated with several antiviral agents.  It can occasionally become 
serious in immune-compromised persons, with generalized skin eruptions and central nervous 
system, pulmonary, hepatic, and pancreatic involvement. 
 
Shingles is found worldwide and has no seasonal variation.  The most striking feature of the 
epidemiology of shingles is the increase in incidence found with increasing age.  Decreasing cell-
mediated immunity (CMI) associated with aging is thought to be responsible for these increased 
rates.  Similarly, the loss of CMI among persons with malignancies and HIV infection is thought to 
be responsible for higher rates of shingles among those populations.  Approximately 20 percent of 
the general population will experience shingles during their lifetime and an estimated 500,000 
episodes of shingles occur annually in the U.S.  Approximately 4 percent of individuals will 
experience a second episode of shingles.   
 
A vaccine to prevent shingles in those who have already had chickenpox has recently been licensed 
for use in adults 60 years of age and older.  It is contraindicated in persons with certain immune-
compromising conditions.  
 
Infectious Agent:  Varicella-zoster virus (VZV, chickenpox virus) 
 
Reservoir:  Humans 
 
Mode of Transmission:  VZV infection is transmitted to susceptible individuals (no history of 
chickenpox or varicella vaccine) by the following means: 
 
1. From shingles cases: 
• direct contact with lesions 
 
2. From disseminated shingles cases, or localized shingles cases in the immunocompromised: 
• airborne 
• direct contact with lesions 
 
Exposure to shingles can result in chickenpox in a susceptible person but cannot cause shingles. 
Exposure to chickenpox does not cause shingles. 
 
Incubation Period:  Shingles has no incubation period; it is caused by reactivation of latent 
infection from primary chickenpox disease. Shingles is infectious until all lesions have crusted over. 
Infectiousness can be prolonged in immunocompromised patients. 
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Diagnosis:  Clinical diagnosis.  Laboratory confirmation is not usually indicated.  However, 
isolation of VZV, or a positive Direct Fluorescence Antibody (DFA), Polymerase Chain Reaction 
(PCR), or Tzanck smear from a clinical specimen can be helpful. 
 
Treatment:  Analgesics and antiviral drugs can be used to treat shingles. 
 
Control:   
Ensure that all healthcare workers are immune to chickenpox at time of employment.  (See 
Attachment A, Revised Proof of Immunity.)  For healthcare workers who have not been immunized 
or do not have serologic proof of immunity, careful screening for history of disease is important.  
Anyone with an uncertain history (regardless of age) should be not considered immune.  In 
healthcare institutions, serologic screening of personnel who have a negative or uncertain history of 
chickenpox is likely to be reliable and cost-effective.  Routine testing for chickenpox immunity 
after two doses of vaccine is not necessary because 99 percent of adults are seropositive after the 
second dose.  Seroconversion, however, does not always result in full protection against disease.   
 
For vaccinated healthcare workers in long-term care facilities who are subsequently exposed to 
shingles (or chickenpox), most should be considered protected.  However, the following measures 
may be considered if immunocompromised patients are present: 
 
• Test for serologic immunity immediately after exposure.  (Latex Agglutination) LA can be 
done quickly and may be a useful post-exposure test.  However, recent evidence has shown 
that false positive can occur, incorrectly categorizing a susceptible person as immune.  
Therefore, less sensitive EIAs are recommended for screening purposes when possible 
. 
• Retest 5-6 days after exposure to determine if an anamnestic response (boosting of antibody 
titres) is present. 
 
• Those workers who remain susceptible should be excluded. 
 
• Alternatively, consider exclusion or reassignment of personnel who do not have detectable 
antibody. 
 
1. Prevent exposure to the case, as follows:  
Staff 
• Staff with localized shingles should cover lesions and should not care for high-risk patients 
until their skin lesions have become dry and crusted. 
• Staff with disseminated shingles and immunocompromised staff with shingles should be 
excluded for the duration of their illness. 
 
Patients 
• Patients with localized shingles should be cared for using standard precautions until all 
lesions are crusted: 
? Only immune staff should care for these patients. 
? Current or prospective roommates should be immune. 
? Gloves should be worn when touching infectious material and during direct patient care. 
Clean gloves should be used before touching mucous membranes and nonintact skin.  
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Gloves should be changed between tasks and procedures on the same patient after 
contact with material that may contain a high concentration of virus.  Gloves should be 
promptly removed after use and before touching noncontaminated items and 
environmental surfaces. 
? Handwashing is necessary after touching the patient and before contact with another 
patient or with noncontaminated items and environmental surfaces, whether or not 
gloves were used. 
? Masks, gowns, and eye protection should be worn during procedures and patient care 
activities likely to generate splashes of blood, bodily fluids, secretions, or excretions. 
? Used patient care equipment and used linen should be handled in a manner that prevents 
skin and mucous membrane exposure and contamination of clothing. 
 
Patients with disseminated shingles and immunocompromised patients with shingles 
(either localized or disseminated) require standard, airborne, and contact precautions.  In 
addition to the standard precautions listed above, the following precautions must also be 
followed: 
? The room should have negative air-pressure ventilation.  However, if this is not 
available, using a private room is acceptable.  If a private room is unavailable, make sure 
roommates are immune and all visitors are screened for history of chickenpox or 
varicella vaccine.  
? Gloves and gowns should be worn at all times. 
? Susceptible staff or visitors should not enter patient room.  If unavoidable, masks should 
be worn.  Persons immune to varicella need not wear masks. 
 
2. Identify all exposed individuals. 
• “Exposure” to uncomplicated shingles is defined as: contact with lesions; for example, 
through close patient care, touching, or hugging. 
• “Exposure” to disseminated shingles and localized or disseminated shingles in an 
immunocompromised person is defined as: 1) contact with lesions (for example, through 
close patient care, touching, or hugging); or 2) sharing indoor airspace with the infectious 
person (for example, occupying the same room).   
 
3. Identify high-risk susceptible patients/staff among the exposed.  Susceptible individuals are 
those without a reliable history of chickenpox or shingles, documentation of prior vaccination 
against chickenpox, or serologic proof of immunity.  (See Attachment A, Revised Proof of 
Immunity.)  High-risk susceptibles include those who are immunosuppressed due to underlying 
medical conditions (including HIV infection), treatment or medications (including steroids), or 
who are susceptible pregnant women.  They are at greater risk for complications from varicella 
and should be referred promptly to their health care provider.  These high-risk susceptibles 
should receive VZIG (varicella zoster immune globulin) as soon as possible within 96 hours of 
exposure.  Please note, bone marrow transplant recipients should be considered susceptible 
regardless of past history of disease.  
4. Identify and vaccinate other exposed susceptibles.  Susceptible individuals are those without 
a reliable history of chickenpox or shingles, documentation of prior vaccination against 
chickenpox, or serologic proof of immunity.  (See Attachment A, Revised Proof of Immunity.)  
If the varicella vaccine is given within 3 (and possibly up to 5) days of exposure to VZV, it can 
prevent disease.  If 5 days have passed since exposure to the case, the vaccine should still be 
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given, as it will protect against possible future exposures.  Chickenpox can still occur in 
susceptible contacts in spite of vaccination, but vaccinating someone who is incubating 
chickenpox or who is immune is not harmful.  See attachments B and C, “Special 
Considerations in the Administration of Varicella Vaccine”, and “Suggested Intervals Between 
Administration of Immunoglobulin Preparations and Measles-Containing and Varicella 
Vaccines”, respectively, for information about groups who should not receive varicella vaccine.  
5. Discharge or isolate exposed susceptible patients. Isolate on contact and airborne 
precautions all exposed, susceptible patients who cannot be discharged from before day 10 after 
exposure, from day 10 through day 21 after exposure.  Those who have received VZIG must 
remain in isolation until day 28. 
 
6. Conduct surveillance for chickenpox for 21 days (one incubation period) after the last 
exposure to shingles.  For those who received VZIG and where immunocompromised 
individuals are involved, surveillance should continue for 28 days. 
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Attachment A 
 
Revised Proof of Immunity 
 
 
 Revised Proof of Immunity to Varicella1  (Updated January 2007) 
 
• Documentation of age-appropriate vaccination against chickenpox: 
o Age 1−12 years at first vaccination: 1 dose2 
o Age >13 years at first vaccination:  2 doses given > 1 month3 apart, or 
• Laboratory evidence of immunity4 or laboratory confirmation of disease, or 
• Born in the US before 19805, or 
• A healthcare provider diagnosis of varicella or healthcare provider verification of history of 
varicella disease6,7, or 
• History of herpes zoster based on healthcare provider diagnosis. 
 
 
1Bone marrow transplant recipients should be considered susceptible regardless of past history 
of disease.   
2While 1 dose given at 1−12 years of age or 2 doses given ≥ 1 month apart at ≥ 13 years of age 
satisfies the school immunization requirement, the ACIP now recommends a 2-dose series age 
groups. 
3For children who have received their first dose before age 13 years and the interval between 
the two doses was at least 28 days, the second dose is considered valid. 
4Commerical assays can be used to assess disease-induced immunity, but they lack adequate 
sensitivity to detect reliably vaccine-induced immunity (may yield false negative results).  
5For healthcare providers and pregnant women, birth before 1980 should not be considered 
evidence of immunity. 
6Self-reported history of chickenpox is also acceptable for adults and college students, with 
review by appropriate healthcare or supervisory staff.   
7Verification of history or diagnosis of typical disease can be done by any healthcare provider 
(e.g., school or occupational clinic nurse, nurse practitioner, physician assistant, physician, 
appropriate supervisory or public health staff).  For people reporting a history of or presenting 
with atypical and/or mild cases, assessment by a physician or their designee is recommended 
and one of the following should be sought:  a) an epidemiologic link to a typical varicella case 
or b) evidence of laboratory confirmation, if laboratory testing was performed at the time of 
acute disease.  When such documentation is lacking, people should not be considered as 
having a valid history of disease, because other diseases may mimic mild atypical varicella. 
 
 
Note: As we move forward into the post-vaccine era, the reliability of history of chickenpox will 
decrease.  At some time in the future, a history of chickenpox will no longer be acceptable proof 
of immunity for those born in or after 1980, unless the illness was laboratory confirmed. 
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Post-Exposure Varicella Vaccine Requirements 
(Updated January 2007) 
 
Vaccination is required for persons: 
• born in or after 19801 or born outside the U.S. (regardless of year of birth), and  
• without history of chickenpox as verified by a healthcare provider, and 
• without serologic proof of immunity 
 
 
 
Additional Doses Required 
 
Number of 
doses received 
previously 
 
Born before 19801 
Born in or after 1980 
(regardless of place of birth) 
 US-born Non US-born <13 years of age > 13 years of age at 
time of first dose 
0 0 12 12 2 
1 0 02 02 1 
2 0 0 0 0 
 
1For healthcare providers and pregnant women, birth before 1980 should not be considered 
evidence of immunity. 
2Two doses of varicella vaccine are recommended.  [While 1 dose given at 1−12 years of 
age or 2 doses given ≥ 1 month apart at ≥ 13 years of age satisfies the school immunization 
requirement, the ACIP now recommends a 2-dose series for all persons all age groups]. 
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Attachment B 
 
Special Considerations in the Administration of Varicella Vaccine 
 
1) The groups listed below should not receive varicella vaccine except as specified in the box.  
Please consult the package insert for a full list of contraindications and precautions. 
 
• Infants less than 12 months of age. 
 
• Pregnant women.  (Women should avoid getting pregnant until ≥ 1 month after vaccination.) 
 
• Those with anaphylactic reaction to neomycin or other vaccine component (consult package 
insert). 
 
• Those on salicylate therapy, due to the risk of Reye syndrome.  (If varicella vaccine has been 
given, salicylate therapy should be deferred for > 6 weeks.) 
 
• Those with severe illness at the time of the scheduled vaccination (temporary contraindication). 
 
• Those with immunocompromising conditions, including malignancies, primary or acquired 
immunodeficiency, and immunosuppressive therapy, except as noted in box below. 
 
 
Groups with Potentially Immunocompromising Conditions 
Eligible to Receive Varicella Vaccine 
 
 
The following persons with immunocompromising conditions are eligible to be 
considered for routine varicella immunization.  However, varicella vaccine 
should not be used as post-exposure prophylaxis.  If exposed, they should 
receive VZIG as soon as possible if within 96 hours of exposure. 
 
● Persons with impaired humoral immunity, e.g. hypogammaglobulinemia, 
dysgammaglobulinemia. 
 
● HIV-infected children who are asymptomatic or mildly symptomatic and 
aged > 12 months with age-specific CD4+ T-lymphocyte percentages of > 
15%,  (If to be vaccinated, these children should receive 2 doses with a 3-
month interval between doses and be monitored for adverse events.  These 
children may have a higher risk of developing a vaccine-associated rash.) 
 
● Children with acute lymphoblastic leukemia (ALL) in remission for at least 
12 consecutive months and conforming to certain other criteria.  (Vaccine 
available through a research protocol.  Health care providers must call 484-
679-2856.) 
 
● Persons on non-suppressive topical, aerosol, or local injections of steroids. 
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● Persons receiving systemic steroids and who are not otherwise 
immunocompromised, if they are receiving < 2 mg/kg of body weight or a 
total of < 20 mg/day of prednisone or its equivalent.  (Persons on higher-dose 
steroid therapy cannot receive varicella vaccine—see section on steroids 
below.) 
 
 
• Those having received blood products (except washed red blood cells), plasma, or immune 
globulin, including VZIG, within the previous 3-11 months (please refer to Attachment C.)  The 
effect of administration of immune globulin on the antibody response to varicella vaccine is not 
known.  Because of potential inhibition of the response, varicella vaccine should not be 
administered after receipt of an immune globulin preparation or a blood product (except washed 
red blood cells), as recommended for measles vaccine.  In addition, varicella vaccine should be 
given > 2 weeks before these blood products.  If IG or a blood product is given during this 2-
week interval, the individual should be reimmunized after the appropriate interval, as specified 
in Attachment C, or tested for varicella immunity at that time and reimmunized if seronegative. 
 
2) Guidelines for administration of live virus vaccines to individuals on steroid therapy*: 
 
 
Steroid Therapy 
 
Recommendations for Deferral 
 
 
High dose systemic steroids daily or on alternate days 
for > 14 days 
(> 2mg/kg QD or > 20 mg QD of prednisone) 
 
 
Defer live virus vaccines for > 1 month 
after treatment has stopped. 
 
High dose systemic steroids daily or on alternate days 
for < 14 days 
(> 2 mg/kg QD or > 20 mg QD prednisone) 
 
Can give live virus vaccines immediately 
after treatment is discontinued.  
However, some experts recommend 
deferring until > 2 weeks after treatment 
has stopped, if possible. 
Low or moderate doses of systemic steroids given daily 
or on alternate days 
(< 2 mg/kg QD or < 20 mg QD of prednisone) 
 
Can give live virus vaccines on 
treatment. 
Physiologic maintenance doses of steroid 
(replacement therapy) 
 
Can give live virus vaccines on 
treatment. 
 
Topical, aerosol or local injections of steroids 
(e.g., skin, aerosol, eyes, intra-articular, bursal, tendon 
injections) 
 
 
Can give live virus vaccines on 
treatment. However, if this therapy is 
prolonged and there is any clinical or 
laboratory evidence of 
immunosuppression, defer for > 1 month 
after treatment has stopped. 
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Individuals with a disease which in itself is considered 
to suppress the immune response and who are receiving 
systemic or locally acting steroids 
 
Should not give live virus vaccines, 
except in special circumstances. 
 
*  Steroid therapy is not a contraindication for administration of killed vaccines. 
 
Adapted from: CDC. General recommendations on immunization: recommendations of the 
Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family 
Physicians (AAFP).  MMWR 2002; 51 (No. RR-2):23.  
 
      
Attachment updated November 2005 
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Attachment C 
 
Suggested Intervals between Administration of Immunoglobulin Preparations 
and Measles-Containing and Varicella Vaccines 
 
 
Product/Indication 
 
Dose, including mg 
immunoglobulin G (IgG)/kg 
body weight1 
Recommended 
interval before 
measles or 
varicella 
vaccination 
(months) 
Respiratory syncytial virus immune 
globulin (IG) monoclonal antibody 
(Synagis™) 
15 mg/kg intramuscularly (IM) None 
Tetanus IG 250 units (10 mg IgG/kg) IM 3 
Hepatitis A IG 
Contact prophylaxis or international travel 
< 3 mos 
International travel 3 – 5 mos 
 
0.02 mL/kg (3.3 mg IgG/kg) IM 
 
0.06 mL/kg (10 mg IgG/kg) IM 
 
3 
 
3 
Hepatitis B IG 0.06 mL/kg (10 mg IgG/kg) IM 3 
Rabies IG 20 IU/kg (22 mg IgG/kg) IM 4 
Varicella IG 125 units/10 kg (20-40 mg IgG/kg) 
IM, maximum 625 units 
5 
Measles prophylaxis IG 
Standard (i.e., nonimmunocompromised) 
contact 
Immunocompromised contact 
 
0.25 mL/kg (40 mg IgG/kg) IM 
 
0.50 mL/kg (80 mg IgG/kg) IM 
 
5 
 
6 
Blood transfusion 
Red blood cells (RBCs), washed 
  
RBCs, adenine-saline added 
Packed RBCs (hematocrit 65%) 
Whole blood (hematocrit 35%-50%) 
Plasma/platelet products 
 
10 mL/kg negligible IgG/kg 
intravenously (IV) 
10 mL/kg (10 mg IgG/kg) IV 
10 mL/kg (60 mg IgG/kg) IV 
10 mL/kg (80-100 mg IgG/kg) IV 
10 mL/kg (160 mg IgG/kg) IV 
 
None 
 
3 
6 
6 
7 
Cytomegalovirus intravenous immune 
globulin (IGIV) 
150 mg/kg maximum IV 6 
Respiratory syncytial virus prophylaxis 
IGIV 
750 mg/kg IV 9 
IGIV 
Replacement therapy for immune 
deficiencies 
Immune thrombocytopenic purpura 
Immune thrombocytopenic purpura 
 
300-400 mg/kg IV 
400 mg/kg IV 
1,000 mg/kg IV 
 
8 
8 
10 
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Kawasaki disease 2 grams/kg IV 11 
Note on other live vaccines:  Blood and other antibody-containing products (except washed red 
blood cells) can also diminish the response to rubella vaccine, and potentially to mumps vaccine.  
Therefore, after immune globulin preparations or other antibody-containing products are received, 
mumps and rubella vaccines should be deferred for > 3 months.  If RSV-IGIV is given, mumps, 
rubella and varicella vaccines should be deferred for > 9 months.  If RSV-IM is given, no deferral 
is needed for any live virus vaccines. 
Adapted from: CDC. General recommendations on immunization: recommendations of the 
Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family 
Physicians (AAFP).  MMWR 2002; 51 (No. RR-2):7. 
 
